Bayer's blood thinner Xarelto appeared to work as well as the standard-therapy combination of Sanofi-Aventis' Lovenox and warfarin in preventing deep vein thrombosis during a late-stage study. Patients who received Xarelto were as likely as those given the standard treatment to develop severe and uncontrolled bleeding.

Full Story:

Related Summaries